Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Primary Hyperoxaluria
Primary Hyperoxaluria
Biotech’s important clinical data readouts
Biotech’s important clinical data readouts
EP Vantage
biotech
Scholar Rock
apitegromab
spinal muscular atrophy
Alnylam
vutrisiran
Dicerna
nedosiran
Primary Hyperoxaluria
FDA
Flag link:
FDA approves Alnylam's first-ever drug for rare kidney disease
FDA approves Alnylam's first-ever drug for rare kidney disease
Bizjournals
Alnylam
FDA
kidney disease
Primary Hyperoxaluria
Flag link:
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Flag link:
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
Flag link:
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
Flag link:
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Flag link:
Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1
Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1
Pharmaceutical Business Review
Dicerna Pharmaceuticals
FDA
breakthrough therapy
Primary Hyperoxaluria
Flag link:
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Alnylam
lumasiran
Primary Hyperoxaluria
Flag link:
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Alnylam
lumasiran
Primary Hyperoxaluria
Flag link: